|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01558 HEC CJ PHARM
Nominal 
9.600 +0.210 (+2.236%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 6,294,585 | 68.082% | 3,744,952 | 913,788 | 2,348,113 | 6,224,024 |
| Cost of Sales | (1,308,821) | 45.606% | (898,878) | (430,089) | (351,547) | (921,822) |
| Gross Profit | 4,985,764 | 75.180% | 2,846,074 | 483,699 | 1,996,566 | 5,302,202 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (29) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 2,126,771 | 5294.884% | 39,422 | (667,184) | 1,010,434 | 2,269,053 | |
| Taxation | (270,945) | -- | 9,817 | 79,460 | (173,023) | (361,868) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 136,798 | 399.920% | 27,364 | 75 | 2,044 | 11,524 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,992,624 | 2501.235% | 76,603 | (587,649) | 839,455 | 1,918,709 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 169,623 | -38.298% | 274,907 | 232,461 | 219,219 | 168,465 |
| Depreciation & Amortisation | 391,274 | 3.688% | 377,357 | 259,816 | 122,726 | 86,185 |
| Directors' Emoluments | 41,563 | 736.951% | 4,966 | 4,457 | 3,963 | 2,020 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 226.000 | 2411.111% | 9.000 | -67.000 | 95.000 | 216.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 10.000 | 65.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | 10.526% | 30.093% |
| Cash flow per share ($) | 1.901 | -- | 1.932 | (0.753) | 1.474 | 2.018 |
| NBV per share ($) | 9.018 | -- | 6.688 | 6.601 | 5.558 | 4.911 |
| Remarks: | Real time quote last updated: 15/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 684,731 |
| %Change | -33.489% |
| EPS / (LPS) | RMB 0.780 |
| NBV Per Share (¥) | RMB 9.847 |